Ibrutinib - Rituximab Beats Chemoimmunotherapy for CLL

Progression - free, overall survival improved in the ibrutinib - rituximab group at three years
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news